News stories about Abaxis (NASDAQ:ABAX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abaxis earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.1073830639237 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
Abaxis (NASDAQ ABAX) opened at $71.18 on Wednesday. Abaxis has a twelve month low of $43.66 and a twelve month high of $78.53. The stock has a market capitalization of $1,557.99, a PE ratio of 65.91, a P/E/G ratio of 11.27 and a beta of 1.27.
Abaxis (NASDAQ:ABAX) last released its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.05. Abaxis had a return on equity of 10.09% and a net margin of 10.51%. The business had revenue of $59.70 million during the quarter, compared to analysts’ expectations of $59.37 million. During the same period in the previous year, the business posted $0.30 earnings per share. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. equities analysts predict that Abaxis will post 1.2 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, March 1st will be issued a $0.16 dividend. The ex-dividend date is Wednesday, February 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.90%. Abaxis’s dividend payout ratio is 59.26%.
A number of research analysts have issued reports on the company. Aegis reissued a “hold” rating on shares of Abaxis in a report on Friday, December 1st. BidaskClub raised Abaxis from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. Bank of America lifted their price objective on Abaxis from $46.00 to $48.00 and gave the company a “sell” rating in a report on Thursday, February 8th. Canaccord Genuity reissued a “hold” rating and set a $65.00 price objective on shares of Abaxis in a report on Monday, January 29th. Finally, TheStreet raised Abaxis from a “c+” rating to a “b-” rating in a report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the stock. Abaxis currently has a consensus rating of “Hold” and a consensus price target of $62.30.
In related news, Director Prithipal Singh sold 2,000 shares of Abaxis stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $74.63, for a total value of $149,260.00. Following the completion of the sale, the director now directly owns 44,000 shares in the company, valued at $3,283,720. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Achim Henkel sold 3,600 shares of Abaxis stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $69.08, for a total value of $248,688.00. Following the completion of the sale, the insider now owns 57,650 shares of the company’s stock, valued at $3,982,462. The disclosure for this sale can be found here. Insiders sold 7,250 shares of company stock valued at $520,593 over the last ninety days. 4.30% of the stock is currently owned by company insiders.
Abaxis Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.